Non-invasive Assessment of Insulin Resistance

描述（由申请人提供）：该项目的长期目标是开发一种新型的无创胰岛素抵抗测试方法。提出的测试是基于在细胞呼吸过程中葡萄糖氧化（Gox）和脂质氧化（Lox）之间的反比关系的既定原则。作为口服葡萄糖耐量试验（OGTT）的一部分，基于呼吸二氧化碳的同位素分析，在给予标准剂量的13c -葡萄糖后，全身Gox/Lox的比例可以精确测量，因此我们建议可以开发一种合适的无创胰岛素抵抗测试。在第一阶段，我们建议在不同胰岛素抵抗的个体中进行有限的临床方案，以证明所提议的测试与目前最有用的胰岛素抵抗临床测试之间的预期反向关系；即全身胰岛素敏感性指数（WBISI）在h阶段，我们将执行一些专门设计的临床方案，以检查潜在重要参数（实验和生理）对该测试性能参数的影响。我们期望i期和h期研究的成功完成会带来一种专门用于非侵入性胰岛素抵抗评估的专有产品方法。

DESCRIPTION (provided by applicant): The long-term objectives of this project are to develop a novel non-invasive test of insulin resistance. The proposed test is based on the well-established principle of inverse relationship between glucose oxidation (Gox) and lipid oxidation (Lox) during cellular respiration. Because the ratio of whole-body Gox/Lox can be measured precisely after administration of a standard dose of 13C-glucose as part of an oral glucose tolerance test (OGTT) based on isotopic analyses of breath CO2, we propose that a suitable noninvasive test of insulin resistance can be developed. During Phase-I, we propose to conduct a limited clinical protocol in individuals who vary across a range of insulin resistance, in order to demonstrate the expected inverse relationship between the proposed test and the currently most useful clinical test of insulin resistance; viz., the whole-body insulin sensitivity index (WBISI). During Phase-H, we will conduct a number of clinical protocols designed specifically to examine the impact of potentially important parameters (experimental and physiological) on performance parameters of this test. We expect that successful completion of research proposed for Phase-I and Phase-H leads to a proprietary product-method specifically for non-invasive assessment of insulin resistance.